Pneumococcal serotype-specific antibodies in children with recurrent oto-sinopulmonary infections
Clinical and Experimental Immunology · 21.01.2025 · 219 (1)
DOI: 10.1093/cei/uxae086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 10.10.2024. Verfasst von Hanadys Ale und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, Allergy, and Rheumatology, Joe DiMaggio Children's Hospital, Hollywood, FL, USA. Hauptthemen laut MEDLINE: Pneumococcal Vaccines, Antibodies, Bacterial, Streptococcus pneumoniae, Pneumococcal Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Low titers to pneumococcal vaccine are a frequent finding in pediatric patients with recurrent oto-sinopulmonary infections. To characterize the pre- and post-immunization antibody trend for each serotype included in the pneumococcal 13-valent conjugate vaccine, in a cohort of pediatric patients with recurrent oto-sinopulmonary infections, this retrospective review identified 182 patients with recurrent oto-sinopulmonary infections (131 required an immune workup and 99 had low pneumococcal titers leading to a pneumococcal 13-valent conjugate vaccine booster). Baseline pneumococcal serotype-specific antibody titers at the initial visit and 6 weeks after the vaccine booster were obtained. An adequate response to the pneumococcal conjugate vaccine was deemed to be a 4-fold increase over baseline and/or a post-immunization titer of 1.3 µg/ml or greater. Overall, The pneumococcal 13-valent conjugate vaccine booster provided a significant improvement in the number of protective titers, increasing from 3.6 serotypes at baseline to 11.1 serotypes at 6 weeks (P < 0.001). This increase correlated with improved clinical outcomes (81% showed no signs of recurrent infection after the first booster and 94% after a second booster). Post-immunization antibody concentrations were significantly higher than at baseline for all serotypes (P < 0.05), and only 8, 9N, and 12F did not exhibit a greater than 4-fold increase (P > 0.05) 6 weeks following booster. There were no differences between patients at different ages in post-immunization titer levels for all serotypes. In pediatric patients with recurrent oto-sinopulmonary infections, an additional pneumococcal booster proved to be effective in the protection of these children against further infections, across all age groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Immunology, Allergy, and Rheumatology, Joe DiMaggio Children's Hospital, Hollywood, FL, USA.
- Department of Pediatrics, Florida International University, Herbert Wertheim College of Medicine, Miami, FL, USA.
- Division of Allergy & Immunology, Nicklaus Children's Hospital, Miami, FL, USA.
- Nicklaus Children's Hospital Research Institute, Miami, FL, USA.
- Allergy and Immunology Care Center of South Florida, Miami, FL, USA.
ORCID-Profile: Hanadys Ale
Zitieren
APA
Ale, H., Calderon, J. G., Gruber, J., Taylor, T., Blouin, W. R., & Hernández-Trujillo, V. P. (2025). Pneumococcal serotype-specific antibodies in children with recurrent oto-sinopulmonary infections. Clinical and Experimental Immunology, 219(1). https://doi.org/10.1093/cei/uxae086
Vancouver
Ale H, Calderon JG, Gruber J, Taylor T, Blouin WR, Hernández-Trujillo VP. Pneumococcal serotype-specific antibodies in children with recurrent oto-sinopulmonary infections. Clinical and Experimental Immunology. 2025;219(1). doi:10.1093/cei/uxae086
BibTeX
@article{Ale2025,
author = {Ale, Hanadys and Calderon, Jose G and Gruber, Joshua and Taylor, Thomas and Blouin, William R and Hernández-Trujillo, Vivian P},
title = {Pneumococcal serotype-specific antibodies in children with recurrent oto-sinopulmonary infections},
journal = {Clinical and Experimental Immunology},
year = {2025},
volume = {219},
number = {1},
doi = {10.1093/cei/uxae086}
}
EUVIMED